NASDAQ:CYTK
Cytokinetics Stock News
$65.27
-0.0100 (-0.0153%)
At Close: May 08, 2024
Cytokinetics shares jump based on results from Phase 2 clinical trial for experimental heart-disease drug
08:13am, Monday, 19'th Jul 2021
Shares of Cytokinetics Inc. soared 33.0% in premarket trading on Monday after the company said a Phase 2 clinical trial for its experimental hypertrophic cardiomyopathy treatment yielded positive resu
Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate
08:12am, Monday, 19'th Jul 2021
Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in hypertrophic cardiomyopathy (HCM). The
Cytokinetics Announces Positive Topline Results of Redwood-HCM
07:36am, Monday, 19'th Jul 2021
Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Car
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 01'st Jul 2021
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2021 it granted stock options to purchase an aggregate of 90,0
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021
07:30am, Wednesday, 30'th Jun 2021
Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure Further Analyses of GALACTIC-
Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress
07:30am, Wednesday, 23'rd Jun 2021
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at Heart Failure 2021, an International Congress of the Euro
Top Line Results of METEORIC-HF Expected in Early 2022
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 02'nd Jun 2021
SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to par
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 01'st Jun 2021
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,50
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
07:30am, Wednesday, 19'th May 2021
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure
01:02pm, Monday, 17'th May 2021
Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (H
SOUTH SAN FRANCISCO, Calif., May 16, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records rel
Cytokinetics' (CYTK) CEO Robert Blum on Q1 2021 Results - Earnings Call Transcript
12:38am, Friday, 07'th May 2021
Cytokinetics' (CYTK) CEO Robert Blum on Q1 2021 Results - Earnings Call Transcript
Cytokinetics to Hold Annual Meeting of Stockholders
04:00pm, Wednesday, 05'th May 2021
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
02:48pm, Monday, 03'rd May 2021
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases